PDB ID: 6F78
Hetero Atom Contents
The number of atoms exceeds 100,000. So, it can not be displayed here.
Select unit:
Select hetatm:
Select chain: Sequence
Data format:
Color scheme of protein:
Code | Name | Style | Show | Link | |
---|---|---|---|---|---|
CVN | 4-[[3,5-bis(trifluoromethyl)phenyl]amino]-1,2-benzoxazol-3-one | PoSSuM | |||
CL | Chloride ion | PoSSuM | |||
NAP | Nadp nicotinamide-adenine-dinucleotide phosphate | PoSSuM |
Code | Name | Show |
---|
Code | Name | Emphasize |
---|
Code | Name | Show |
---|
Download interaction data: 6F78
Structure summary
Code : | 6F78 PDBj RCSB PDB PDBe | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Header : | OXIDOREDUCTASE | ||||||||||||
Title : | Potent and selective Aldo-Keto Reductase 1C3 (AKR1C3) inhibitors based on the benzoisoxazole moiety: Application of a Bioisosteric Scaffold Hopping Approach to Flufenamic acid | ||||||||||||
Release Data : | 2018-04-04 | ||||||||||||
Compound : |
|
||||||||||||
Source : |
|
||||||||||||
Authors : | Goyal, P., Wahlgren, W.Y., Friemann, R. | ||||||||||||
Keywords : | aldo-keto reductase 1C3, AKR1C3, 17betaHSD5, Prostate cancer, CRPC, bioisosterism, scaffold hopping, inhibitors, oxidoreductase | ||||||||||||
Exp. method : | X-RAY DIFFRACTION ( 1.300 Å ) | ||||||||||||
Citation : |
Potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitors based on the benzoisoxazole moiety: application of a bioisosteric scaffold hopping approach to flufenamic acid.
Pippione, A.C.,Carnovale, I.M.,Bonanni, D.
et al.
PubMed: 29602039 |
Reaction
Chain : | A, B | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
UniProt : | P42330 (AK1C3_HUMAN) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|